Thompson Siegel & Walmsley LLC Invests $420,000 in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Thompson Siegel & Walmsley LLC acquired a new stake in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) during the 2nd quarter, Holdings Channel reports. The fund acquired 127,724 shares of the company’s stock, valued at approximately $420,000.

A number of other hedge funds have also recently bought and sold shares of ETON. Victory Capital Management Inc. acquired a new position in Eton Pharmaceuticals in the 4th quarter valued at $123,000. Acadian Asset Management LLC increased its stake in Eton Pharmaceuticals by 13.7% in the first quarter. Acadian Asset Management LLC now owns 156,386 shares of the company’s stock valued at $585,000 after purchasing an additional 18,898 shares during the last quarter. Westside Investment Management Inc. boosted its stake in Eton Pharmaceuticals by 2.0% in the 2nd quarter. Westside Investment Management Inc. now owns 585,400 shares of the company’s stock worth $1,926,000 after buying an additional 11,440 shares during the last quarter. Finally, Opaleye Management Inc. boosted its stake in Eton Pharmaceuticals by 4.1% in the 4th quarter. Opaleye Management Inc. now owns 2,529,887 shares of the company’s stock worth $11,081,000 after buying an additional 99,617 shares during the last quarter. Institutional investors and hedge funds own 27.86% of the company’s stock.

Eton Pharmaceuticals Stock Up 6.8 %

Shares of ETON opened at $5.50 on Tuesday. The firm has a market cap of $141.30 million, a PE ratio of 137.50 and a beta of 1.30. The company’s fifty day moving average is $4.02 and its two-hundred day moving average is $3.76. Eton Pharmaceuticals, Inc. has a fifty-two week low of $3.03 and a fifty-two week high of $5.64.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.05). The firm had revenue of $9.07 million for the quarter, compared to analysts’ expectations of $10.00 million. Eton Pharmaceuticals had a negative net margin of 21.31% and a negative return on equity of 43.62%. As a group, equities research analysts anticipate that Eton Pharmaceuticals, Inc. will post -0.15 earnings per share for the current year.

Insider Buying and Selling

In other Eton Pharmaceuticals news, major shareholder Opaleye Management Inc. acquired 57,500 shares of the firm’s stock in a transaction on Tuesday, September 10th. The stock was bought at an average cost of $4.65 per share, for a total transaction of $267,375.00. Following the completion of the purchase, the insider now directly owns 2,660,000 shares in the company, valued at $12,369,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 14.89% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $9.00 price objective on shares of Eton Pharmaceuticals in a report on Wednesday, September 4th.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.